The role of anticoagulants in atrial fibrillation and anti-platelet agents in ischaemic heart disease as separate treatments are undisputed with clear benefits. The combination of both has become more frequent, though making safe and effective treatment more complex.
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.